Home Cart Sign in  
Chemical Structure| 1213269-23-8 Chemical Structure| 1213269-23-8

Structure of WZ4002
CAS No.: 1213269-23-8

Chemical Structure| 1213269-23-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WZ4002 is an irreversible inhibitor of mutant EGFR (L858R) and EGFR (T790M) with IC50 of 2 nM and 8 nM respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WZ4002

CAS No. :1213269-23-8
Formula : C25H27ClN6O3
M.W : 494.97
SMILES Code : C=CC(NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3OC)=NC=C2Cl)=C1)=O
MDL No. :MFCD16621244
InChI Key :ITTRLTNMFYIYPA-UHFFFAOYSA-N
Pubchem ID :44607530

Safety of WZ4002

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of WZ4002

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR (L858R/T790M), IC50:8 nM

    EGFR (L858R), IC50:2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PC9 cells 100 nM weekly To evaluate the effect of WZ4002 alone or in combination with trametinib on cell viability, results showed that combination therapy significantly delayed the emergence of resistance. PMC4824006
HCC827 cells 100 nM weekly To evaluate the effect of WZ4002 alone or in combination with trametinib on cell viability, results showed that combination therapy significantly delayed the emergence of resistance. PMC4824006
H1975 cells 100 nM weekly To evaluate the effect of WZ4002 alone or in combination with trametinib on cell viability, results showed that combination therapy significantly delayed the emergence of resistance. PMC4824006
PC9 cells 1 μM 72 hours To evaluate the resistance mechanism of WZ4002 in PC9 cells, it was found that WZ4002 inhibited EGFR phosphorylation, but AKT phosphorylation remained in the resistant cells. PMC3994895
WZR cells 1 μM 6 hours To evaluate the effect of WZ4002 on WZR cells, it was found that WZ4002 inhibited EGFR phosphorylation, but AKT phosphorylation remained in the resistant cells. PMC3994895
PC9 WZR_1 1.5 μM 96 hours To investigate the sensitivity of WZ4002-resistant cells to selumetinib, results showed that in the presence of WZ4002, selumetinib significantly inhibited cell growth and ERK phosphorylation. PMC4605607
H1975 cells 0.5 or 1 μM 48 hours To assess the toxic effects of WZ4002 on H1975 cells, results showed that WZ4002 alone or in combination with KU55933 reduced cell viability. PMC10629204
H1993 cells 0.5 or 1 μM 48 hours To assess the toxic effects of WZ4002 on H1993 cells, results showed that WZ4002 alone or in combination with KU55933 reduced cell viability. PMC10629204

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice PC9 GR4 xenograft model oral 10 mg/kg once every 2 weeks for 6 weeks To evaluate the effect of WZ4002 alone or in combination with trametinib on tumor growth, results showed that combination therapy significantly delayed tumor recurrence and achieved tumor cure in some mice. PMC4824006
mice EGFRL858R + T790M transgenic model 50 mg/kg Twice a week for 2 weeks To test the efficacy of combination therapy with AZD9291 and selumetinib on AZD9291-resistant tumors, results showed that the combination significantly inhibited tumor growth. PMC4605607
Mice EGFR T790M (L858R/T790M and DelE746_A750/T790M) NSCLC Oral gavage 5 mg/kg/day AZD9291 + 5 mg/kg twice daily selumetinib 3 months of AZD9291 treatment followed by 1-2 months of combination treatment with AZD9291 and selumetinib To evaluate the efficacy of WZ4002 in EGFR T790M mouse models PMC3477553

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.10mL

2.02mL

1.01mL

20.20mL

4.04mL

2.02mL

References

[1]Zannetti A, Iommelli F, et al. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. J Nucl Med. 2012 Mar;53(3):443-50.

[2]Zhou W, Ercan D, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009 Dec 24;462(7276):1070-4.

[3]Kawabata S, Mercado-Matos JR, et al. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Rep. 2014 Jun 26;7(6):1824-32.

[4]Ercan D, Xu C, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012 Oct;2(10):934-47.

[5]Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009 Dec 24;462(7276):1070-4.

[6]Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 2013 Feb;3(2):168-81.

[7]Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012 Mar 15;18(6):1663-71.

[8]Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Yokose T, Kameda Y, Koizume S, Miyagi Y. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83.

 

Historical Records

Categories